Balyasny Asset Management
ABBV icon

Balyasny Asset Management’s AbbVie ABBV Stock Holding History

Balyasny Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$892K Sell
4,100
-4,200
-51% -$932K ﹤0.01% 2129
2025
Q4 		$1.9M Sell
8,300
-94,900
-92% -$21.6M ﹤0.01% 1895
2025
Q3 		$23.9M Buy
103,200
+90,600
+719% +$18.4M 0.03% 639
2025
Q2 		$2.34M Sell
12,600
-77,300
-86% -$14.4M ﹤0.01% 1657
2025
Q1 		$18.8M Buy
89,900
+1,400
+2% +$272K 0.03% 624
2024
Q4 		$15.7M Sell
88,500
-14,500
-14% -$2.67M 0.02% 766
2024
Q3 		$20.3M Buy
103,000
+91,900
+828% +$17.2M 0.03% 622
2024
Q2 		$1.9M Sell
11,100
-6,200
-36% -$1.03M ﹤0.01% 1549
2024
Q1 		$3.15M Sell
17,300
-9,900
-36% -$1.71M 0.01% 1390
2023
Q4 		$4.22M Buy
27,200
+7,500
+38% +$1.09M 0.01% 1180
2023
Q3 		$2.94M Buy
+19,700
New +$2.89M 0.01% 1272
2023
Q2 		– Sell
-59,500
Closed -$9.48M – 2214
2023
Q1 		$9.48M Hold
59,500
– – 0.02% 798
2022
Q4 		$9.62M Hold
59,500
– – 0.03% 765
2022
Q3 		$7.99M Buy
59,500
+44,500
+297% +$6.39M 0.02% 788
2022
Q2 		$2.3M Buy
+15,000
New +$2.29M 0.01% 1336
2021
Q3 		– Sell
-6,700
Closed -$755K – 1877
2021
Q2 		$755K Buy
+6,700
New +$755K ﹤0.01% 1416
2020
Q2 		– Sell
-80,000
Closed -$6.09M – 1080
2020
Q1 		$6.09M Buy
+80,000
New +$6.81M 0.07% 358
2017
Q4 		– Sell
-300,200
Closed -$26.7M – 2026
2017
Q3 		$26.7M Buy
+300,200
New +$22.9M 0.1% 260
2016
Q1 		– Sell
-571,200
Closed -$33.8M – 1239
2015
Q4 		$33.8M Buy
+571,200
New +$32.9M 0.23% 121
2015
Q3 		– Sell
-300,000
Closed -$20.2M – 1117
2015
Q2 		$20.2M Buy
300,000
+200,000
+200% +$13.1M 0.12% 215
2015
Q1 		$5.85M Buy
+100,000
New +$6.04M 0.05% 452

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management's ABBV Position: Q1 2026 in Review

Balyasny Asset Management reduced its AbbVie (ABBV) stake by 25% in Q1 2026, selling an estimated $2.66M and leaving 35,130 shares worth $7.64M. The position accounts for 0.01% of the portfolio, ranked #1156.

Balyasny Asset Management first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $240M in Q2 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Balyasny Asset Management held 35,130 shares of AbbVie worth $7.64M as of Q1 2026.
  • Balyasny Asset Management sold 11,973 AbbVie shares in Q1 2026, an estimated $2.66M.
  • AbbVie made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1156 holding.
  • Balyasny Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
  • Balyasny Asset Management's AbbVie position peaked at $240M in Q2 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.